Daewon Pharmaceutical Co., Ltd.
003220.KS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$186.04B
Close$
$19949.81
147.5% upside
Current Fair Value
147.5% upsideUndervalued by 147.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $186.04 Billion |
|---|---|
| Enterprise Value | $374.24 Billion |
| Annual dividend | $250.00 |
| Dividend yield | 2.88% |
| Earnings per Share | $-64.37 |
| Beta | 0.18 |
| Outstanding Shares | 21,433,000 |
Return
| Return on Equity | 0.98% |
|---|---|
| Return on Assets | 0.46% |
| Return on Invested Capital | -17.94% |
Valuation & Multiples
| P/E Ratio | 70.81 |
|---|---|
| PEG | -30.14 |
| Price to Sales | 0.28 |
| Price to Book Ratio | 0.63 |
| Enterprise Value to Revenue | 0.61 |
| Enterprise Value to EBIT | -5.71 |
| Enterprise Value to Net Income | 142 |
| Total Debt to Enterprise | 0.57 |
| Debt to Equity | 0.79 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 7, 2026
EPS Estimate
$114.71
Consensus analyst estimateRevenue Estimate
$152.20 B
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$156.81
Consensus analyst estimateRevenue Estimate
$145.80 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Daewon Pharmaceutical Co., Ltd.
1,349 employees
CEO: Seung-Ryel Baek
Established in 1958 and headquartered in Seoul, South Korea, Daewon Pharmaceutical Co., Ltd. is a well-regarded pharmaceutical enterprise specializing in the development, manufacturing, and distribution of a comprehensive range of medica...